Request Demo

Last update 20 Mar 2025

Cyclopentolate Hydrochloride

Last update 20 Mar 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(±)-cyclopentolate, 1-hydroxy-α-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester, 2-(dimethylamino)ethyl 1-hydroxy-α-phenylcyclopentaneacetate

+ [16]

Target

mAChRs

Action

antagonists

Mechanism

mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)

Therapeutic Areas

Nervous System DiseasesEye DiseasesOther Diseases

Active Indication

Eye DiseasesCycloplegiaIritis+ [2]

Inactive Indication-

Originator Organization

Santen Pharmaceutical Co., Ltd.

Active Organization

Santen Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (23 Sep 1971),

Eye Diseases

Regulation-

Structure/Sequence

Molecular FormulaC17H26ClNO3

InChIKeyRHKZVMUBMXGOLL-UHFFFAOYSA-N

CAS Registry5870-29-1

View All Structures (2)

Clinical Trials associated with Cyclopentolate Hydrochloride

ChiCTR2400084750

/ SuspendedEarly Phase 1IIT

Comparison of the effects of pupil dilation and ciliary muscle paralysis of 1% tropicamide, 0.5% tropicamide and 1% cyclopentolate

Start Date31 May 2024

Sponsor / Collaborator-

NCT06077682

/ RecruitingPhase 4IIT

Tropicamide Versus Cyclopentolate for Cycloplegic Refraction in Pediatric Patients With Esotropia: A Randomized Clinical Trial

The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for cycloplegic refractions in pediatric populations with esotropia. This will be a prospective double-blinded randomized clinical trial (RCT), multi-center, with randomized sequencing of cycloplegic agent; each patient received one agent at one visit, and the other agent in the next visit (2 different visits ≥ 1 week apart) within 3 months.

Start Date01 Sep 2023

Sponsor / Collaborator

The Islamic Hospital

[+2]

NCT05442801

/ CompletedPhase 4IIT

Tropicamide Versus Cyclopentolate Objective Refraction in Pediatric Population

The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for cycloplegic refractions in pediatric populations. This will be a prospective double-blinded randomized clinical trial (RCT), multi center, with randomized sequencing of cycloplegic agent; each patient received one agent at one visit, and the other agent in the next visit (2 different visits ≥ 1 week apart) within 3 months.

Start Date01 Mar 2022

Sponsor / Collaborator

The Islamic Hospital

100 Clinical Results associated with Cyclopentolate Hydrochloride

100 Translational Medicine associated with Cyclopentolate Hydrochloride

100 Patents (Medical) associated with Cyclopentolate Hydrochloride

707

Literatures (Medical) associated with Cyclopentolate Hydrochloride

01 Jan 2025·Ophthalmic and Physiological Optics

Impact of proxymetacaine on the dynamics of cyclopentolate in White 6‐ to 7‐year‐olds

Article

Author: O'Dwyer, Veronica ; Doyle, Megan ; Harrington, Síofra

AbstractPurposeThis study compared the efficacy of cyclopentolate hydrochloride at 10‐, 20‐ and 30‐min post‐instillation in White 6‐ to 7‐year‐olds, with and without prior instillation of proxymetacaine hydrochloride. The primary aim was to determine if accurate autorefraction values can be obtained sooner than the current standard of 30‐min post‐cycloplegia. The secondary aim was to investigate whether proxymetacaine hydrochloride enhances the efficiency of cyclopentolate.MethodsParticipants were 112 White 6‐ to 7‐year‐olds from the Child Eye Health Study. The right eye received 0.5% proxymetacaine hydrochloride and 1.0% cyclopentolate hydrochloride, and the left eye received only 1.0% cyclopentolate hydrochloride. Non‐cycloplegic and cycloplegic refractive error (at 0, 10, 20 and 30 min) was measured using a binocular, open‐field autorefractometer. Data were analysed through paired t‐tests, concordance analysis, linear regression, equivalence testing and Bland–Altman analysis, using the 95% limits of agreement.ResultsMean spherical equivalent refraction (SER) (SD) in the right eye at 0‐, 10‐, 20‐ and 30‐min post‐instillation was 0.62 (1.45) D, 1.52 (1.80) D, 1.64 (1.81) D and 1.72 (1.80) D, respectively. Mean left eye SER (SD) were 0.68 (1.24) D, 1.42 (1.66) D, 1.56 (1.66) D and 1.68 (1.72) D, respectively. Bland–Altman analysis showed a high level of agreement, and equivalence testing confirmed that there was no clinically significant difference in SER at 20 and 30 min in both eyes (within ±0.50 D), with mean differences of 0.08 (0.23) D in the right eye and 0.13 (0.30) D in the left eye (p = 0.21). However, SER at 10 and 30 min were equivalent in the right eye only.ConclusionsAccurate autorefraction values can be obtained 20‐min post‐instillation of 1.0% cyclopentolate in white children aged 6–7 years, potentially reducing clinical testing times. Proxymetacaine pre‐instillation allows for reliable measurements as early as 10‐min post‐instillation of cyclopentolate. Further research is needed to validate these findings in non‐White populations and to determine the safe discharge time post‐proxymetacaine instillation.

01 Jan 2025·Journal of Optometry

Influence of lens thickness on the accommodative range in healthy eyes

Article

Author: Rozema, Jos J ; Koppen, Carina ; Pierscionek, Barbara K ; Vermeulen, Louise ; Van Os, Luc

BACKGROUNDThe maximum accommodative range is a useful indication of visual function. It decreases with age, but the exact cause of this decrease is not fully understood. It is associated with the increasing rigidity of the lens and changes to the lens shape, as well as the geometry of the zonular attachments. This work aims to determine the relationship between the accommodative range and lens shape in a group of healthy young adults.METHODSThis study includes 40 emmetropic participants between 20 and 30 years of age. They filled in a questionnaire and underwent accommodation measurements using the RAF Convergence Rule and the Negative Lens Test. After a drop of Tropicamide 0.5 % and Cyclopentolate 1 %, participants underwent measurements with autorefractor, Scheimpflug tomography (Pentacam HR, Oculus), anterior segment Optical Coherence Tomography and optical biometry.RESULTSThe accommodative range did not correlate significantly (p>0.05) with any of the lenticular or ocular parameters considered, such as lens thickness, lens radii of curvature, axial length, or corneal power.CONCLUSIONThe crystalline lens shape does not affect the accommodative range of the eye. This may be due to the smaller deformation required to bring a thicker lens to the same level of accommodation as a thinner lens. The amount of force on the zonular fibres may therefore be similar, in all lenses, regardless of the lens shape.

01 Jan 2025·JAMA Ophthalmology

In-Office Suprachoroidal Viscopexy for Acute Rhegmatogenous Retinal Detachment

Article

Author: Park, John ; Melo, Isabela Martins ; Batawi, Hatim ; Muni, Rajeev H. ; Pecaku, Aurora ; Minelli, Tomas ; Demian, Sueellen

ImportanceIn-office suprachoroidal viscopexy (SCVEXY) is a relatively new procedure for rhegmatogenous retinal detachment (RRD), but minimal information is available regarding outcomes and safety.ObjectiveTo report outcomes with in-office SCVEXY for primary acute RRD.Design, Setting, and ParticipantsThis retrospective case series was conducted at St Michael’s Hospital in Toronto, Ontario, Canada from June 2023 to February 2024 among consecutive patients with primary acute RRDs who presented with retinal tears that were reachable with the current in-office SCVEXY technique in the temporal or nasal retina.ExposureSuprachoroidal injection of 0.6 mL of sodium hyaluronate, 2.3%, at the break location using a 30-gauge needle with a custom-made guard leaving 1 mm of the needle exposed. Laser retinopexy was applied around the break once reattachment was achieved.Main Outcome and MeasuresThe primary outcome was primary anatomic reattachment rate with SCVEXY and recovery of function and anatomic integrity.ResultsAmong 6 patients, 2 patients (33.3%) were female, and mean (SD) patient age was 52.5 (19.7) years. The final follow-up duration for each patient was 510, 420, 360, 360, 330, and 320 days, respectively. Baseline VAs were hand motions, counting fingers, 20/100, 20/100, 20/25, and hand motions for patients 1 through 6, respectively. A dome-shaped suprachoroidal buckle was present in all cases after the procedure. Five of 6 patients (83.3%) achieved anatomic reattachment with no retinal displacement or outer retinal folds, and these patients could resume normal activity immediately after the procedure with no restrictions. The mean (SD) logMAR VA at 3 months was +0.46 (0.34) (Snellen 20/57). The viscoelastic persisted in the suprachoroidal space as confirmed by multimodal imaging for 10, 14, 21, 13, 24, and 14 days, respectively, and the retina remained attached during the entire postoperative follow-up period. One patient’s SCVEXY failed due to inadequate viscoelastic at the posterior edge of the retinal break, and this patient underwent a successful pneumatic retinopexy. One patient developed a localized choroidal effusion unrelated to the SCVEXY site following laser retinopexy that resolved in 1 week associated with topical prednisolone, 1%, 4 times daily and cyclopentolate, 1%, twice daily.Conclusions and RelevanceIn this case series, the outcomes of these 6 cases suggest that SCVEXY may offer durable retinal reattachment in RRD. However, randomized clinical trial data, larger sample sizes, and longer-term follow-up are necessary to assess the risk-benefit profile of SCVEXY compared with the standard of care.

News (Medical) associated with Cyclopentolate Hydrochloride

12 Aug 2024

·www.prnewswire.com

OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship

SHANGHAI, Aug. 12, 2024 /PRNewswire/ -- On August 13th 2024, Ocumension Therapeutics (" OcuMension") announced an agreement with Alcon Inc. (" Alcon", and collectively with OcuMension, the " Parties") where OcuMension will acquire or secure commercialization rights in China to a portfolio of Alcon dry eye treatments and procedural drops, including several commercially available products and one development-stage product. The scope of the agreement will also cover areas of R&D, manufacturing and commercialization in China. In connection with the transfer of these rights, OcuMension will issue 139,161,120 shares to Alcon, accounting for 16.71% of the total share capital (post-issuance). Consequently, Alcon becomes one of the largest shareholders of OcuMension. Under the terms of the arrangement, each company has granted the other company a right of first negotiation over future products. OcuMension, as a leading Chinese ophthalmic pharmaceutical platform company, focuses on integrating comprehensive capabilities across the entire lifecycle of ophthalmic drug development—from research and development to commercialization. OcuMension possesses a portfolio of 25 pharmaceutical assets. Alcon, the global leader in eye care, offers a broad portfolio of products to enhance sight and improve lives for patients in more than 140 countries. Under this arrangement, OcuMension will acquire outright, Tears Natural® Forte, Bion Tears, Alcaine®, Fluorescite, and Cyclogyl, in the Chinese market and the commercialization rights in China to Systane® Ultra and AR-15512, a novel topical drug candidate for dry eye. Under the terms of this agreement, OcuMension will manufacture those products acquired outright for China after a transition period. OcuMension will also develop, manufacture and commercialize AR-15512 in China. The addition of these seven mature products and AR-15512 to OcuMension's portfolio is expected to further enhance OcuMension's leadership in the ophthalmology field in the China market. Through the acquisition of these products, OcuMension expects to be capable of providing more comprehensive and advanced treatment solutions, further meeting patient needs and expanding market share. The Parties expect that the framework of this agreement will allow both Parties to further promote technological advancements and innovations in the field of ophthalmology. Ophthalmic diseases are internationally recognized as one of the highly focused medical sub-sectors, with innovative treatment solutions for ophthalmology still awaiting development. Based on this, OcuMension will continue to focus on bringing safer, more efficient, and cutting-edge treatment solutions to global ophthalmic patients, meeting the growing medical needs of patients. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, Alcon offers the broadest portfolio of products to enhance sight and improve people's lives. Alcon's Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Alcon's more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at . About OcuMension OcuMension is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. OcuMension's vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since its inception, OcuMension has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug's development cycle, from research and development, manufacturing to commercialization. OcuMension believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors. Advisors Morrison Foerster acted as legal advisor to OcuMension in this transaction. Lazard acted as financial advisor to Alcon and Gibson Dunn as its legal advisor. SOURCE OcuMension

AcquisitionLicense out/in

100 Deals associated with Cyclopentolate Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01002	Cyclopentolate Hydrochloride	S01FA04	DB00979

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eye Diseases	Japan	Santen Pharmaceutical Co., Ltd.	23 Sep 1971
Cycloplegia	-	-	-
Cycloplegia	United States	-	-
Iritis	-	-	-
Mydriasis	United States	-	-
Mydriasis	-	-	-
Uveitis	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02909140 (CTgov)	Not Applicable	Cataract	3	Topical phenylephrine 2.5%+Topical cyclopentolate 1%+Intracameral Lidocaine 1% (Topical Mydriasis)	cdgiwxibgp(wleixzyytj) = xihwrdbdsw wvvzgfkcly (lcdwfpieme, asxedtgtac - iinhjwvedb) View more	-	10 Sep 2019
				Intracameral Lidocaine 1% (Intracameral Mydriasis)	bgmjzwatow(buajdmdosx) = ttjqnduuvc zwlttmrssz (xmmdzyvwsk, qbpnsxgyta - mltujigyfk) View more
Pubmed \| Curr Eye Res	Not Applicable	Retinopathy of Prematurity	25	Cyclopentolate	akjzmhdkhb(hundqbljuf) = Preterm infants undergoing Retinopathy of Prematurity Eye Exams (ROPEE) may experience adverse events, possibly from systemic absorption of cyclopentolate. nbhkqqjqbk (bqndmptguz ) View more	-	01 Dec 2016
				Cyclopentolate
ARVO2015	Not Applicable	-	8	Cyclopentolate 1%	(wqaauhxrww) = hpkcjpwgpk ovwvtmfyqj (lkshpcbjaj ) View more	-	01 Jun 2015
ARVO2013	Not Applicable	Myopia	28	cyclopentolate (Myopic children)	erxovqnzix(wrffakgnac) = yvnkfnfjre qtqygqzfql (ealjtuinsp ) View more	-	01 Jun 2013
Multi-Ethnic Pediatric Eye Disease Study (ARVO2008)	Not Applicable	Refractive Errors	24	Cyclopentolate	hljpsiiikv(jtcthlmxvl) = dahwbwkeck vnzrxcnbhp (qtaekjdhxe, 0.85) View more	Positive	01 May 2008
				Atropine	hljpsiiikv(jtcthlmxvl) = fpdkfcmhln vnzrxcnbhp (qtaekjdhxe, 0.85)
P114 (AAO2000)	Not Applicable	-	-	Tropicamide 1%	myuytbynjk(xlmdfwjwgb) = upzyuwtxfh cwlutjmaci (npvhhmtjza, 0.78)	-	22 Oct 2000
				Cyclopentolate 1%	myuytbynjk(xlmdfwjwgb) = xiokczljkv cwlutjmaci (npvhhmtjza, 0.78)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cyclopentolate Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation